The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy

Journal of Cardiology

Volumn 68, Issue 1, 2016, Pages 49-56

  Klopotowski, Mariusz ^a   Kukula, Krzysztof ^a   Malek, Lukasz A ^a   Spiewak, Mateusz ^a   Polanska Skrzypczyk, Magdalena ^a   Jamiolkowski, Jacek ^b   Dabrowski, Maciej ^a   Baranowski, Rafal ^a   Klisiewicz, Anna ^a   Kusmierczyk, Mariusz ^a   Jasinska, Anna ^a   Jarmus, Ewelina ^a   Kruk, Mariusz ^a   Ruzyllo, Witold ^a   Witkowski, Adam ^a   Chojnowska, Lidia ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cardiac magnetic resonance; Hypertrophic cardiomyopathy; Imaging biomarker; Late gadolinium enhancement; Sudden cardiac death

Indexed keywords

GADOBUTROL; CONTRAST MEDIUM; GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CONTRAST ENHANCEMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; YOUNG ADULT; CARDIAC MUSCLE; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; EVALUATION STUDY; FIBROSIS; HEART; HEART LEFT VENTRICLE FUNCTION; KAPLAN MEIER METHOD; MAGNETIC RESONANCE ANGIOGRAPHY; PATHOLOGY; PROCEDURES; RISK FACTOR;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DISEASE-FREE SURVIVAL; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; GADOLINIUM; HEART; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84941243942     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.07.020     Document Type: Article

References (38)

1. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785-789.
2. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E., Yancy C.W. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011, 58:2703-2738.
3. Minami Y., Haruki S., Hagiwara N. Phenotypic overlap in hypertrophic cardiomyopathy: apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol 2014, 64:463-469.
4. McKenna W.J., Deanfield J.E. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child 1984, 59:971-975.
5. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
6. Maron B.J., Casey S.A., Hauser R.G., Aeppli D.M. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003, 42:882-888.
7. Maron B.J., Olivotto I., Spirito P., Casey S.A., Bellone P., Gohman T.E., Graham K.J., Burton D.A., Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000, 102:858-864.
8. Elliott P.M., Gimeno J.R., Thaman R., Shah J., Ward D., Dickie S., Tome Esteban M.T., McKenna W.J. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006, 92:785-791.
9. Elliott P.M., Poloniecki J., Dickie S., Sharma S., Monserrat L., Varnava A., Mahon N.G., McKenna W.J. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36:2212-2218.
10. Monserrat L., Elliott P.M., Gimeno J.R., Sharma S., Penas-Lado M., McKenna W.J. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003, 42:873-879.
11. Spirito P., Autore C., Rapezzi C., Bernabo P., Badagliacca R., Maron M.S., Bongioanni S., Coccolo F., Estes N.A., Barilla C.S., Biagini E., Quarta G., Conte M.R., Bruzzi O., Maro B.J. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009, 119:1703-1710.
12. Dimitrow P.P., Chojnowska L., Rudzinski T., Piotrowski W., Ziólkowska L., Wojtarowicz A., Wycisk A., Dabrowska-Kugacka A., Nowalany-Kozielska E., Sobkowicz B., Wróbel W., Aleszewicz-Baranowska J., Rynkiewicz A., Loboz-Grudzien K., Marchel M., et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 2010, 31:3084-3093.
13. Gimeno J.R., Tome-Esteban M., Lofiego C., Hurtado J., Pantazis A., Mist B., Lambiase P., McKenna W.J., Elliott P.M. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009, 30:2599-2605.
14. Maron B.J., Spirito P., Shen W.K., Haas T.S., Formisano F., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Lawrenz T., Boriani G., Estes N.A., Favale S., Piccininno M., Winters S.L., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007, 298:405-412.
15. Schinkel A.F., Vriesendorp P.A., Sijbrands E.J., Jordaens L.J., ten Cate F.J., Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy. Circ Heart Fail 2012, 5:552-559.
16. Zipes D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M., Gregoratos G., Klein G., Moss A.J., Myerburg R.J., Priori S.G., Quinones M.A., Roden D.M., Silka M.J., Tracy C., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006, 48:e247-e346.
17. Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., Hagege A.A., Lafont A., Limongelli G., Mahrholdt H., McKenna W.J., Mogensen J., Nihoyannopoulos P., Nistri S., Pieper P.G., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014, 35:2733-2779.
18. O'Mahony C., Jichi F., Pavlou M., Monserrat L., Anastasakis A., Rapezzi C., Biagini E., Gimeno J.R., Limongelli G., McKenna W.J., Omar R.Z., Elliott P.M. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014, 35:2010-2020.
19. Ismail T.F., Jabbour A., Gulati A., Mallorie A., Raza S., Cowling T.E., Das B., Khwaja J., Alpendurada F.D., Wage R., Roughton M., McKenna W.J., Moon J.C., Varnava A., Shakespeare C., et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 2014, 100:1851-1858.
20. Chan R.H., Maron B.J., Olivotto I., Pencina M.J., Assenza G.E., Haas T., Lesser J.R., Gruner C., Crean A.M., Rakowski H., Udelson J.E., Rowin E., Lombardi M., Cecchi F., Tomberli B., et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 2014, 130:484-495.
21. Spiewak M., Malek L.A., Misko J., Chojnowska L., Milosz B., Klopotowski M., Petryka J., Dabrowski M., Kepka C., Ruzyllo W. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol 2010, 74:149-153.
22. Hawass N.E. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol 1997, 70:360-366.
23. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., Petrou M., Pennell D.J. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004, 43:2260-2264.
24. Kwon D.H., Smedira N.G., Rodriguez E.R., Tan C., Setser R., Thamilarasan M., Lytle B.W., Lever H.M., Desai M.Y. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009, 54:242-249.
25. O'Hanlon R., Grasso A., Roughton M., Moon J.C., Clark S., Wage R., Webb J., Kulkarni M., Dawson D., Sulaibeekh L., Chandrasekaran B., Bucciarelli-Ducci C., Pasquale F., Cowie M.R., McKenna W.J., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:867-874.
26. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012, 5:370-377.
27. Maron M.S., Appelbaum E., Harrigan C.J., Buros J., Gibson C.M., Hanna C., Lesser J.R., Udelson J.E., Manning W.J., Maron B.J. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008, 1:184-191.
28. Bruder O., Wagner A., Jensen C.J., Schneider S., Ong P., Kispert E.M., Nassenstein K., Schlosser T., Sabin G.V., Sechtem U., Mahrholdt H. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010, 56:875-887.
29. Rubinshtein R., Glockner J.F., Ommen S.R., Araoz P.A., Ackerman M.J., Sorajja P., Bos J.M., Tajik A.J., Valeti U.S., Nishimura R.A., Gersh B.J. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010, 33:51-58.
30. Hen Y., Iguchi N., Utanohara Y., Takada K., Machida H., Takayama M., Sumiyoshi T. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 2014, 78:927-937.
31. Fujita T., Konno T., Yokawa J., Masuta E., Nagata Y., Fujino N., Funada A., Hodatsu A., Kawashiri M.A., Yamagishi M., Hayashi K. Increased extent of myocardial fibrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyarrhythmias. J Cardiol 2015, 66:63-68.
32. Magri D., De Cecco C.N., Piccirillo G., Mastromarino V., Serdoz A., Muscogiuri G., Ricotta A., Gregori M., Marino L., Cauti F.M., Pagannone E., Musumeci M.B., Maruotti A., Autore C. Myocardial repolarization dispersion and late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Circ J 2014, 78:1216-1223.
33. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., Pennel D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003, 41:1561-1567.
34. Chan R.H., Maron B.J., Olivotto I., Assenza G.E., Hass T.S., Lesser J.R., Gruner C., Crean A.M., Rakowski H., Rowin E., Udelson J., Lombardi M., Tomberli B., Spiroto P., Formisano F., et al. Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 2015, 116:436-441.
35. Spiewak M., Malek L.A., Petryka J., Mazurkiewicz L., Marczak M., Biernacka E.K., Kowalski M., Hoffman P., Demkow M., Miśko J., Ruzyłło W. Determinants of left- and right-ventricular ejection fractions in patients with repaired tetralogy of Fallot: a cardiac magnetic resonance imaging study. Pol Arch Med Wewn 2013, 12:539-546.
36. Rudolph A., Abdel-Aty H., Bohl S., Boyé P., Zagrosek A., Dietz R., Schulz-Menger J. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009, 53:284-291.
37. Maron B.J., Spirito P., Ackerman M.J., Casey S.A., Semsarian C., Estes N.A., Shannon K.M., Ashley E.A., Day S.M., Pacileo G., Formisano F., Devoto E., Anastasakis A., Bos J.M., Woo A., et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 2013, 61:1527-1535.
38. Chaowu Y., Shihua Z., Jian L., Wei F. Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy. Circ Heart Fail 2013, 6:1013-1020.